MVP Laboratories partners with
MJ Biologics to combat PRRSV
Laboratories and MJ Biologics have successfully collaborated to
produce a USDA licensed autogenous MJPRRS® vaccine that can help
swine producers tackle the complex PRRSV disease problem.
MJPRRS Viral Antigen Concentrate Subunit Vaccine Technology and MJPRRS Grouping Technology are combined with MVP's proprietary EMULSIGEN-D
adjuvant to produce the second generation MJPRRS Vaccine. This
vaccine contains the maximum concentrations of PRRS viral antigens
in the presence of MVP's extraordinary adjuvant.
two companies have been working on scale-up of MJ Biologics' unique
technology in MVP's new production facility in Omaha, NE. MJPRRS vaccines produced by MVP Laboratories must pass stringent quality
control testing prior to release to assure the presence of optimal
levels of antigenic mass. At this time, MVP reports that it is able
to produce the unique vaccine in 100,000 dose serials.